Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Commercial Sponsor
Bristol-Myers Squibb (BMS)
Summary
Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive CC-92480 + carfilzomib + dexamethasone). In the Active Comparator Arm, participants will receive carfilzomib + dexamethasone.